Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer
BOSTON and SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing...
Day: November 12, 2024
Lifeward Ltd. Reports Third Quarter 2024 Financial Results
Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for...
OrganOx and eGenesis Announce Exclusive Clinical Co-Development Agreement for Treatment of Patients with Liver Failure in the Acute Setting
Partnership aims to advance a novel liver support system integrating a leading organ preservation platform with whole biologic livers to...
Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem
First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native,...
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the...
Transpire Bio Announces Corporate Office Expansion
WESTON, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics...
Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44
HOUSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is honored to announce it was selected...
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial...
Created by the McGill University Health Centre (MUHC) Foundation, the third MUHC’s Got Talent presented by Heritage MD featured performers vying for votes and fundraising for causes at the MUHC
MONTREAL, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MUHC health care staff and supporters took to the stage at Beanfield Theatre...
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract...
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
GERMANTOWN, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on...
Acuitive Technologies Receives FDA 510(k) Clearance for CITREPORE™, A New Synthetic Bioactive Bone Void Filler for Orthopedic Procedures
ALLENDALE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Acuitive Technologies, Inc. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market CITREPORE, a...
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect...
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
LifeMD to Participate in Three Investor Conferences During November
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services,...
Tria Federal Announces Acquisition of Softrams, Creating a New Federal Health Powerhouse
Combination creates scaled, vertically integrated provider of technology and advisory capabilities serving critical federal health and public safety missions Tria...
iCAD’s ProFound Detection Version 4.0 Gains FDA Clearance
Provides 22% Overall Improvement in Detecting Challenging and Aggressive Cancer Subtypes and Enables Clinicians to Incorporate a Prior Exam into...
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted...
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...